JP2013542985A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542985A5 JP2013542985A5 JP2013539788A JP2013539788A JP2013542985A5 JP 2013542985 A5 JP2013542985 A5 JP 2013542985A5 JP 2013539788 A JP2013539788 A JP 2013539788A JP 2013539788 A JP2013539788 A JP 2013539788A JP 2013542985 A5 JP2013542985 A5 JP 2013542985A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical
- formulation according
- pharmaceutical formulation
- intestinal motility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 108090000790 Enzymes Proteins 0.000 claims 7
- 102000004190 Enzymes Human genes 0.000 claims 7
- 230000001079 digestive Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 229940088598 Enzyme Drugs 0.000 claims 5
- 230000000968 intestinal Effects 0.000 claims 5
- 230000004899 motility Effects 0.000 claims 5
- 239000007789 gas Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 229920002261 Corn starch Polymers 0.000 claims 2
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 claims 2
- 208000007906 Intestinal Disease Diseases 0.000 claims 2
- QCDYQQDYXPDABM-UHFFFAOYSA-N Phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 claims 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 235000010980 cellulose Nutrition 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 239000008120 corn starch Substances 0.000 claims 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229940020899 hematological Enzymes Drugs 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- MNBSXKSWDLYJHN-UHFFFAOYSA-N 2,4,6-trimethylbenzene-1,3,5-triol Chemical compound CC1=C(O)C(C)=C(O)C(C)=C1O MNBSXKSWDLYJHN-UHFFFAOYSA-N 0.000 claims 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N Alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 claims 1
- 239000004382 Amylase Substances 0.000 claims 1
- 108010065511 Amylases Proteins 0.000 claims 1
- 102000013142 Amylases Human genes 0.000 claims 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N Bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M Butylscopolamine Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 claims 1
- 229940106157 CELLULASE Drugs 0.000 claims 1
- 108010059892 Cellulase Proteins 0.000 claims 1
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229960000913 Crospovidone Drugs 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 1
- 229940040461 Lipase Drugs 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N Loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001571 Loperamide Drugs 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinylpyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical group N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims 1
- 229940055729 Papain Drugs 0.000 claims 1
- 108090000526 Papain Proteins 0.000 claims 1
- 108090000284 Pepsin A Proteins 0.000 claims 1
- 229960001553 Phloroglucinol Drugs 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- IKGXIBQEEMLURG-BKUODXTLSA-N Rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims 1
- 229940081967 Rutin Drugs 0.000 claims 1
- 229940083037 Simethicone Drugs 0.000 claims 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N Simethicone Chemical group C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- FKHIFSZMMVMEQY-UHFFFAOYSA-N Talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 claims 1
- LORDFXWUHHSAQU-UHFFFAOYSA-N Trimebutine Chemical group C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 LORDFXWUHHSAQU-UHFFFAOYSA-N 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 239000006096 absorbing agent Substances 0.000 claims 1
- 229960003550 alosetron Drugs 0.000 claims 1
- 235000019418 amylase Nutrition 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 229960003571 butylscopolamine Drugs 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229940059442 hemicellulase Drugs 0.000 claims 1
- 108010002430 hemicellulase Proteins 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 108090001060 lipase Proteins 0.000 claims 1
- 102000004882 lipase Human genes 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 229910052919 magnesium silicate Inorganic materials 0.000 claims 1
- 235000019792 magnesium silicate Nutrition 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000019834 papain Nutrition 0.000 claims 1
- 229940111202 pepsin Drugs 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229930002876 rutin Natural products 0.000 claims 1
- 235000005493 rutin Nutrition 0.000 claims 1
- 229960004555 rutoside Drugs 0.000 claims 1
- 229950009846 scopolamine butylbromide Drugs 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005345 trimebutine Drugs 0.000 claims 1
- 229940030049 trimethylphloroglucinol Drugs 0.000 claims 1
- 229960001322 trypsin Drugs 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
Claims (15)
- 腸管疾患の予防又は治療のための、錠剤、被覆錠剤又はカプセルの形態の経口投与用医薬組成物又は製剤であって、
腸運動調節剤、ガス滞留防止剤、消化酵素、結合剤、希釈剤、吸収剤、崩壊剤、滑沢剤及びグライディング剤を含むことを特徴とする、医薬組成物又は製剤。 - 前記腸運動調節剤が、トリメブチン、フェノベリン、メベベリン、ジシクロベリン、エチルブロミド、アロセトロン、ロペラミド、フロログルシノール、トリメチルフロログルシノール、ブチルスコポラミン及びパルゲベリンから成る群から選択される、請求項1に記載の医薬製剤。
- 前記結合剤が、ヒドロキシプロピルセルロース、コーンスターチ、プロピルセルロース及びメチルセルロースから成る群から選択される、請求項1に記載の医薬製剤。
- 前記希釈剤が、ラクトース、結晶セルロース、リン酸水素カルシウム及びマンニトールから成る群から選択される、請求項1に記載の医薬製剤。
- 前記吸収剤が、リン酸水素カルシウム、アルミニウム及びマグネシウムシリケート、コロイド状二酸化ケイ素並びに結晶セルロースから成る群から選択される、請求項1に記載の医薬製剤。
- 前記崩壊剤が、クロスカルメロースナトリウム、コーンスターチ及びクロスポビドンから成る群から選択される、請求項1に記載の医薬製剤。
- 前記滑沢剤が、ステアリン酸マグネシウム、タルク及びステアリン酸から成る群から選択される、請求項1に記載の医薬製剤。
- 前記グライディング剤が、コロイド状二酸化ケイ素である、請求項1に記載の医薬製剤。
- 前記ガス防止剤が、シメチコンである、請求項1に記載の医薬製剤。
- 前記消化酵素が、α−D−ガラクトシダーゼ、アミラーゼ、β−D−ガラクトシダーゼ、セルラーゼ、ヘミセルラーゼ、リパーゼ、パパイン、ペプシン、キモトリプシン、ルチン及びトリプシンから成る群から選択される、請求項1に記載の医薬製剤。
- 前記消化酵素が、酵素エネルギー450U/galのα−D−ガラクトシダーゼである、請求項10に記載の医薬製剤。
- 腸管疾患用の、腸運動調節剤、ガス滞留防止剤及び消化酵素をベースとした錠剤、被覆錠剤又はカプセルの形態の経口投与用医薬組成物の調製方法であって、
事前に準備した腸運動調節剤、ガス滞留防止剤及び消化酵素、前記腸運動調節剤及び前記消化酵素を加湿するための結合溶液を混合し、篩過する工程、
混合物を粉砕、乾燥及び篩過する工程、
経口投与用の医薬製剤を得る工程
を含むこと特徴とする方法。 - 前記成分を、温度30〜60℃で乾燥させ、前記組成物が、5%以下の最終残留湿度に達する、請求項12に記載の方法。
- 前記混合物を、メッシュサイズ420〜2,000ミクロンで篩過する、請求項13に記載の方法。
- 治療で使用するための、請求項1に記載の組成物又は医薬製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2010012479A MX2010012479A (es) | 2010-11-16 | 2010-11-16 | Composicion farmaceutica de administracion oral para el tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retencion de gases y enzimas digestivas y proceso para su preparacion. |
MXMX/A/2010/012479 | 2010-11-16 | ||
PCT/MX2011/000138 WO2012067481A2 (es) | 2010-11-16 | 2011-11-15 | Composición farmacéutica de administración oral para el tratamiento del síndrome de intestino irritable, a base de un modificador de la motilidad intestinal, un agente que previene la retención de gases y enzimas digestivas y proceso para su preparación |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016116423A Division JP6250100B2 (ja) | 2010-11-16 | 2016-06-10 | 腸運動調節剤、ガス滞留防止剤及び消化酵素を含む過敏性腸症候群の治療のための経口投与用医薬組成物及びその調製方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013542985A JP2013542985A (ja) | 2013-11-28 |
JP2013542985A5 true JP2013542985A5 (ja) | 2014-04-24 |
JP6166179B2 JP6166179B2 (ja) | 2017-07-19 |
Family
ID=46084557
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013539788A Active JP6166179B2 (ja) | 2010-11-16 | 2011-11-15 | 腸運動調節剤、ガス滞留防止剤及び消化酵素を含む過敏性腸症候群の治療のための経口投与用医薬組成物及びその調製方法 |
JP2016116423A Active JP6250100B2 (ja) | 2010-11-16 | 2016-06-10 | 腸運動調節剤、ガス滞留防止剤及び消化酵素を含む過敏性腸症候群の治療のための経口投与用医薬組成物及びその調製方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016116423A Active JP6250100B2 (ja) | 2010-11-16 | 2016-06-10 | 腸運動調節剤、ガス滞留防止剤及び消化酵素を含む過敏性腸症候群の治療のための経口投与用医薬組成物及びその調製方法 |
Country Status (28)
Country | Link |
---|---|
US (2) | US20130344145A1 (ja) |
EP (1) | EP2641598B1 (ja) |
JP (2) | JP6166179B2 (ja) |
KR (1) | KR101958031B1 (ja) |
CN (1) | CN103429237A (ja) |
AR (1) | AR083888A1 (ja) |
AU (1) | AU2011329916B2 (ja) |
BR (1) | BR112013012100B8 (ja) |
CA (1) | CA2818129C (ja) |
CL (1) | CL2013001331A1 (ja) |
CO (1) | CO6731095A2 (ja) |
CR (1) | CR20130219A (ja) |
DO (1) | DOP2013000107A (ja) |
EC (1) | ECSP13012642A (ja) |
ES (1) | ES2685784T3 (ja) |
GT (1) | GT201300119A (ja) |
MA (1) | MA34729B1 (ja) |
MX (1) | MX2010012479A (ja) |
PE (2) | PE20171321A1 (ja) |
PL (1) | PL2641598T3 (ja) |
PT (1) | PT2641598T (ja) |
RS (1) | RS57857B1 (ja) |
RU (1) | RU2581920C2 (ja) |
TR (1) | TR201812643T4 (ja) |
UA (1) | UA111480C2 (ja) |
UY (1) | UY33733A (ja) |
WO (1) | WO2012067481A2 (ja) |
ZA (1) | ZA201303518B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6385642B2 (ja) * | 2013-02-28 | 2018-09-05 | 小林製薬株式会社 | 内服用組成物 |
US9402885B2 (en) * | 2013-07-15 | 2016-08-02 | Alfa Wassermann S.P.A. | Method of treating GERD with alpha and beta galactosidases |
CA2920844A1 (en) * | 2013-08-09 | 2015-02-12 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
WO2016114734A1 (en) * | 2015-01-16 | 2016-07-21 | Biofarma Ilaç Sanayi Ve Ticaret A. Ş. | Pharmaceutical formulation of trimebutine maleate and simethicone comprising acidifying agent |
IT201700006355A1 (it) * | 2017-01-20 | 2018-07-20 | Neilos S R L | Composizione per il trattamento dei disturbi gastrointestinali |
CN109200278A (zh) * | 2018-10-08 | 2019-01-15 | 毛玉坤 | 腔镜去粘液消泡剂及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ233582A (en) * | 1989-05-16 | 1992-05-26 | Akpharma Inc Formerly Aek Dev | Oral composition comprising alpha-galactosidase |
JPH03275622A (ja) * | 1990-03-26 | 1991-12-06 | Teisan Seiyaku Kk | マレイン酸トリメブチンを含有する経口固形製剤 |
KR920002149A (ko) * | 1990-07-03 | 1992-02-28 | 안드레아 엘. 콜비 | 비스테로이드계 소염제에 의해 유발된 위장 장애 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법 |
CA2166730A1 (en) * | 1993-07-06 | 1995-01-19 | Robert T. Sims | H2 antagonist-gastrointestinal motility agent combinations |
US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
US6676933B2 (en) * | 2001-05-23 | 2004-01-13 | Osmotica Corp. | Pharmaceutical composition containing mosapride and pancreatin |
KR100467147B1 (ko) * | 2002-06-25 | 2005-01-24 | 주식회사 서울제약 | 이중코팅층을 갖는 제피정의 제조방법 |
CA2521369A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
US20070020249A1 (en) * | 2005-04-29 | 2007-01-25 | Downs Bernard W | Compositions for prevention and treatement of symptoms of gastrointestinal distress |
US20070105878A1 (en) * | 2005-10-03 | 2007-05-10 | Andrew Reaume | Purine formulations and methods for managing disorders |
DE102005049649A1 (de) * | 2005-10-18 | 2007-04-19 | Pro Natura Gesellschaft für gesunde Ernährung mbH | Zusammensetzung zur Linderung von Beschwerden des Magen-Darm-Trakts |
CO5790164A1 (es) * | 2006-08-10 | 2007-08-31 | Procaps S A | Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento |
JP2008056567A (ja) * | 2006-08-29 | 2008-03-13 | Kowa Co | 胃腸疾患の治療又は予防のための医薬 |
-
2010
- 2010-11-16 MX MX2010012479A patent/MX2010012479A/es active IP Right Grant
-
2011
- 2011-11-14 UY UY0001033733A patent/UY33733A/es not_active Application Discontinuation
- 2011-11-15 KR KR1020137015297A patent/KR101958031B1/ko active IP Right Grant
- 2011-11-15 RU RU2013127270/15A patent/RU2581920C2/ru active IP Right Revival
- 2011-11-15 TR TR2018/12643T patent/TR201812643T4/tr unknown
- 2011-11-15 EP EP11841251.9A patent/EP2641598B1/en active Active
- 2011-11-15 PT PT11841251T patent/PT2641598T/pt unknown
- 2011-11-15 PE PE2017001077A patent/PE20171321A1/es unknown
- 2011-11-15 CN CN2011800651242A patent/CN103429237A/zh active Pending
- 2011-11-15 UA UAA201307590A patent/UA111480C2/uk unknown
- 2011-11-15 PE PE2013001060A patent/PE20140380A1/es active IP Right Grant
- 2011-11-15 CA CA2818129A patent/CA2818129C/en active Active
- 2011-11-15 PL PL11841251T patent/PL2641598T3/pl unknown
- 2011-11-15 ES ES11841251.9T patent/ES2685784T3/es active Active
- 2011-11-15 RS RS20181010A patent/RS57857B1/sr unknown
- 2011-11-15 BR BR112013012100A patent/BR112013012100B8/pt active IP Right Grant
- 2011-11-15 AU AU2011329916A patent/AU2011329916B2/en active Active
- 2011-11-15 US US13/885,627 patent/US20130344145A1/en not_active Abandoned
- 2011-11-15 WO PCT/MX2011/000138 patent/WO2012067481A2/es active Application Filing
- 2011-11-15 JP JP2013539788A patent/JP6166179B2/ja active Active
- 2011-11-16 AR ARP110104272A patent/AR083888A1/es not_active Application Discontinuation
-
2013
- 2013-05-09 GT GT201300119A patent/GT201300119A/es unknown
- 2013-05-14 CL CL2013001331A patent/CL2013001331A1/es unknown
- 2013-05-14 ZA ZA2013/03518A patent/ZA201303518B/en unknown
- 2013-05-14 CR CR20130219A patent/CR20130219A/es unknown
- 2013-05-15 DO DO2013000107A patent/DOP2013000107A/es unknown
- 2013-05-27 EC ECSP13012642 patent/ECSP13012642A/es unknown
- 2013-06-10 MA MA36002A patent/MA34729B1/fr unknown
- 2013-06-14 CO CO13143134A patent/CO6731095A2/es unknown
-
2016
- 2016-06-10 JP JP2016116423A patent/JP6250100B2/ja active Active
- 2016-12-14 US US15/378,589 patent/US20170087227A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013542985A5 (ja) | ||
EP1390015A1 (en) | Taste-masking of highly water-soluble drugs | |
CN102791271B (zh) | 抗凝剂的溶出改善方法 | |
CN101703513B (zh) | 阿司匹林和氯吡格雷或其药学上可接受的盐的复方缓释制剂 | |
CN106176771B (zh) | 一种拉米夫定-替诺福韦复方片及其制备方法 | |
RU2013127270A (ru) | Перорально вводимая фармацевтическая композиция для лечения синдрома раздраженного кишечника, содержащая регулятор перистальтики кишечника, средство, которое предотвращает задержку газов, и пищеварительные ферменты, и способ ее получения | |
CN103705478B (zh) | 含有富马酸替诺福韦二吡呋酯的口服片剂 | |
CN104706604A (zh) | 一种吡仑帕奈冻干口崩片及其制备方法 | |
CN105919962A (zh) | 一种达比加群酯片剂及其制备方法 | |
CN101204389A (zh) | 一种含有重酒石酸卡巴拉汀的药物组合物及其制备方法 | |
CN103006612A (zh) | 一种赖诺普利迟释缓释片剂及其制备方法 | |
WO2011038574A1 (en) | Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | |
JP5614445B2 (ja) | 経口投与用粒子状医薬組成物 | |
CN102470108A (zh) | 非pH依赖型制剂(6-(5-氯-2-吡啶基)-5-[(4-甲基-1-哌嗪基)羰氧基]-7-氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪) | |
JP2013502452A (ja) | オチロニウムの直接圧縮錠 | |
CN102727456B (zh) | 药物口腔崩解片及其制备方法 | |
JP2010202579A (ja) | アカルボースを含有する口腔内崩壊剤 | |
JP2015533174A (ja) | ピロカルピンの医薬製剤 | |
JP2022520170A (ja) | アファビシン製剤、その作製方法及びその使用 | |
JP2009503057A (ja) | 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物 | |
WO1999026606A2 (en) | SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS | |
CN105816436B (zh) | 一种泮托拉唑肠溶微丸、泮托拉唑肠溶缓控释片剂及其制备方法 | |
CN102335148A (zh) | 一种复方奥美拉唑片及其制备方法 | |
WO2017107857A1 (zh) | 一种含有二胺衍生物或其盐的固体药物组合物 | |
WO2012067482A3 (es) | COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y α-D-GALAGTOSIDASA |